Christopher R. Cline - Sep 3, 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Sep 3, 2025
Transactions value $
-$10,608
Form type
4
Date filed
9/5/2025, 04:05 PM
Previous filing
Aug 28, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cline Christopher R. CHIEF FINANCIAL OFFICER C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 2025-09-05 0001943192

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Sale -$8.26K -454 -0.49% $18.20 92.2K Sep 3, 2025 Direct F1
transaction TVTX Common Stock Sale -$2.35K -119 -0.13% $19.71 92.1K Sep 4, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F2 This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.